Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer

International Journal of Hematology

Volumn 90, Issue 4, 2009, Pages 446-454

  Lusher, Jeanne M ^a   Scharrer, Inge ^b,c  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

FVIII; Hemophilia; Inhibitors; Pathogen safety; Recombinant FVIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

CLINICAL TRIAL; CONTAMINATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; REVIEW; VIRUS TRANSMISSION;

CLINICAL TRIALS AS TOPIC; DISEASE TRANSMISSION, INFECTIOUS; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 73449109462     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0435-x     Document Type: Review

References (45)

1. CA Ludlam WG Powderly S Bozzette M Diamond MA Koerper R Kulkarni, et al. 2006 Clinical perspectives of emerging pathogens in bleeding disorders Lancet 367 252 261 10.1016/S0140-6736(06)68036-7 1:CAS:528:DC%2BD28Xls1WisQ%3D%3D 16427495 (Pubitemid 43107671)
2. CR Hay 2006 The epidemiology of factor VIII inhibitors Haemophilia 12 23 28 10.1111/j.1365-2516.2006.01362.x 1:CAS:528:DC%2BD28XhtlGiu7rE 17123390 (Pubitemid 44741499)
3. B Neugebauer C Drai M Haase A Hilger B Keller-Stanislawski P Laitinen-Parkkonen, et al. 2008 Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines Haemophilia 14 142 144 1:CAS:528:DC%2BD1cXis1ajsbg%3D 18070062
4. K Peerlinck C Hermans 2006 Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy Haemophilia 12 579 590 10.1111/j.1365-2516.2006.01338.x 1:CAS:528:DC%2BD2sXhtFKgtA%3D%3D 17083507 (Pubitemid 44710297)
5. K Peerlinck J Arnout M Di Giambattista JG Gilles R Laub M Jacquemin, et al. 1997 Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate Thromb Haemost 77 80 86 1:CAS:528:DyaK2sXhtFSkt7Y%3D 9031454
6. FR Rosendaal HK Nieuwenhuis HM van den Berg H Heijboer EP Mauser-Bunschoten J van der Meer, et al. 1993 A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands Dutch Hemophilia Study Group Blood 81 2180 2186 1:STN:280: DyaK3s3ivFOlsw%3D%3D 8471777
7. RM Lawn GA Vehar 1986 The molecular genetics of hemophilia Sci Am 254 48 54 1:CAS:528:DyaL28Xhs1Kiur0%3D 3006240
8. BG Boedeker 2001 Production processes of licensed recombinant factor VIII preparations Semin Thromb Hemost 27 385 394 10.1055/s-2001-16891 1:CAS:528:DC%2BD3MXmvFKru74%3D 11547361 (Pubitemid 32802894)
9. E Gomperts R Lundblad R Adamson 1992 The manufacturing process of recombinant factor VIII, recombinate Transfus Med Rev 6 247 251 1:STN:280:DyaK3s%2Fktl2hsg%3D%3D 1421823
10. (2007) Advate European Public Assessment Report Scientific Discussion. European Medicines Agency.
11. NS Key C Negrier 2007 Coagulation factor concentrates: past, present, and future Lancet 370 439 448 10.1016/S0140-6736(07)61199-4 1:CAS:528: DC%2BD2sXosFKktb8%3D 17679021 (Pubitemid 47176658)
12. RY Dodd EPt Notari SL Stramer 2002 Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population Transfusion (Paris) 42 975 979 1:STN:280: DC%2BD38nislKqsw%3D%3D
13. R Phelps K Robbins T Liberti A Machuca G Leparc M Chamberland, et al. 2004 Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor Transfusion (Paris) 44 929 933
14. EW Fiebig CM Heldebrant RI Smith AJ Conrad EL Delwart MP Busch 2005 Intermittent low-level viremia in very early primary HIV-1 infection J Acquir Immune Defic Syndr 39 133 137 15905727
15. ME Chamberland 2002 Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? Clin Infect Dis 34 797 805 10.1086/338787 11850862 (Pubitemid 34194851)
16. ® Bayer Haemophilia 8 6 9 10.1046/j.1351-8216.2001.00117.x 1:CAS:528: DC%2BD38XksFSlur8%3D 11966845 (Pubitemid 34498621)
17. R Jiang T Monroe R McRogers PJ Larson 2002 Manufacturing challenges in the commercial production of recombinant coagulation factor VIII Haemophilia 8 Suppl 2 1 5 10.1046/j.1351-8216.2001.00115.x 11966844
18. K Cai TM Gierman J Hotta CJ Stenland DC Lee DY Pifat, et al. 2005 Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens BioDrugs 19 79 96 10.2165/00063030- 200519020-00002 1:CAS:528:DC%2BD2MXksVygsbY%3D 15807628 (Pubitemid 40559474)
19. (2009) Kogenate Bayer product information. European Medicines Agency.
20. (2007) Kogenate Bayer variation application EMEA/H/C/275/II/30. European Medicines Agency.
21. MP Piet S Chin AM Prince B Brotman AM Cundell B Horowitz 1990 The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation Transfusion (Paris) 30 591 598 1:CAS:528:DyaK3MXjvFSrsA%3D%3D
22. B Horowitz ME Wiebe A Lippin MH Stryker 1985 Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations Transfusion (Paris) 25 516 522 1:CAS:528:DyaL28Xls1altg%3D%3D
23. DC Lee CJ Stenlanda RC Hartwella EK Forda K Caia JLC Millera, et al. 2000 Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein J Virol Methods 84 77 89 10.1016/S0166-0934(99) 00135-4 1:CAS:528:DC%2BD3cXhtVaisrw%3D 10644089
24. K Cai JL Miller CJ Stenland KJ Gilligan RC Hartwell JC Terry, et al. 2002 Solvent-dependent precipitation of prion protein Biochim Biophys Acta 1597 28 35 1:CAS:528:DC%2BD38XjsFOjs7s%3D 12009399
25. DC Lee CJ Stenland JL Miller K Cai EK Ford KJ Gilligan, et al. 2001 A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins Transfusion (Paris) 41 449 455 1:CAS:528:DC%2BD3MXjslyntr8%3D
26. Hematology/Cardiology GCDTA (2008) Periodic safety update report-antihemophilic factor (Recombinant) formulated with sucrose. Bayer Healthcare.
27. JM Lusher S Arkin CF Abildgaard RS Schwartz 1993 Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group N Engl J Med 328 453 459 10.1056/NEJM199302183280701 1:STN:280:DyaK3s7jtlamtg%3D%3D 8421474 (Pubitemid 23056434)
28. J Lusher C Abildgaard S Arkin PM Mannucci R Zimmermann L Schwartz, et al. 2004 Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation J Thromb Haemost 2 574 583 10.1111/j.1538-7933.2004. 00646.x 1:CAS:528:DC%2BD2cXjslWntLg%3D 15102011 (Pubitemid 40185680)
29. C Rothschild Y Laurian EP Satre A Borel Derlon H Chambost P Moreau, et al. 1998 French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance Thromb Haemost 80 779 783 1:CAS:528:DyaK1cXnsF2juro%3D 9843171
30. GC White D DiMichele K Mertens C Negrier IR Peake C Prowse, et al. 1999 Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Thromb Haemost 81 462 1:CAS:528:DyaK1MXhvFWlt7k%3D 10102478
31. S Seremetis JM Lusher CF Abildgaard CK Kasper R Allred D Hurst 1999 Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group Haemophilia 5 9 16 10.1046/j.1365-2516.1999.00191.x 1:STN:280:DyaK1M3jsVeqtw%3D%3D 10215942 (Pubitemid 29094898)
32. RS Schwartz CF Abildgaard LM Aledort S Arkin AL Bloom HH Brackmann, et al. 1990 Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group N Engl J Med 323 1800 1805 1:STN:280:DyaK3M%2FmtFyntw%3D%3D 2123300
33. AR Giles GE Rivard J Teitel I Walker 1998 Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy Transfus Sci 19 139 148 10.1016/S0955-3886(98)00024-1 1:STN:280:DyaK1M%2Fit12muw%3D%3D 10187039 (Pubitemid 28438925)
34. W Kreuz JC Gill C Rothschild MJ Manco-Johnson JM Lusher E Kellermann, et al. 2005 Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation Thromb Haemost 93 457 467 1:CAS:528:DC%2BD2MXivVGms7g%3D 15735795
35. Norenberg C, Gorina E (2007) Statistical analysis plan for an integrated analysis of rFactor VIII (Kogenate FS). Bayer HealthCare AG.
36. J Oldenburg V Ivaskevicius J Schroder CR Muller A Ganguly 2006 Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII Thromb Haemost 95 903 905 1:CAS:528:DC%2BD28Xlt1Wgurc%3D 16676088
37. TC Abshire HH Brackmann I Scharrer K Hoots C Gazengel JS Powell, et al. 2000 Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group Thromb Haemost 83 811 816 1:CAS:528:DC%2BD3cXkslOhtLk%3D 10896230
38. A Yoshioka K Fukutake J Takamatsu A Shirahata 2006 Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data Int J Hematol 84 158 165 10.1532/IJH97.06019 1:CAS:528:DC%2BD28XhtVygtLjK 16926139 (Pubitemid 44343980)
39. R Musso E Santagostino A Faradji A Iorio J van der Meer J Ingerslev, et al. 2008 Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting Thromb Haemost 99 52 58 1:CAS:528:DC%2BD1cXhtlWju78%3D 18217134
40. JC Delumeau C Ikegawa C Yokoyama V Haupt 2008 An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A Thromb Haemost 100 32 37 1:CAS:528:DC%2BD1cXhtFeiu7zM 18612535
41. M Rubinger D Lillicrap GE Rivard J Teitel M Carcao C Hensman, et al. 2008 A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose Haemophilia 14 281 286 10.1111/j.1365-2516. 2007.01634.x 1:CAS:528:DC%2BD1cXksFSntrg%3D 18194308 (Pubitemid 351338688)
42. E Singleton J Smith M Kavanagh B Nolan B White 2007 Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII Thromb Haemost 98 1188 1192 1:CAS:528:DC%2BD1cXnsV2hug%3D%3D 18064312
43. Maas-Enriquez M, Gorina E, Bajwa N, Lemm G. Inhibitor development in patients with hemophilia A treated with sucrose-formulated recombinant factor VIII. J Thromb Haemost. 2007;5(Suppl 2):P-T-138.
44. D Keeling C Tait M Makris 2008 Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology Haemophilia 14 671 684 10.1111/j.1365-2516.2008.01695.x 1:CAS:528: DC%2BD1cXps1GlsLg%3D 18422612 (Pubitemid 352016021)
45. Scharrer I, Brackmann HH, Sultan Y, Abshire T, Gazengel C, Ragni M, et al. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia. 2000;6:614-8.